Comparative Antithrombotic Potencies of Direct Thrombin Inhibitors and Low-Molecular-Weight Heparins in an Ex Vivo Human Experimental Thrombosis Model

Job Harenberg; Kawei Zokai; Lukas Piazolo; Tavidar Fenyvesi; Ingrid Jörg

doi:10.1055/s-2002-34307

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2002; 28(4): 379-382
DOI: 10.1055/s-2002-34307

Comparative Antithrombotic Potencies of Direct Thrombin Inhibitors and Low-Molecular-Weight Heparins in an Ex Vivo Human Experimental Thrombosis Model

Job Harenberg, Kawei Zokai, Lukas Piazolo, Tavidar Fenyvesi, Ingrid Jörg

4th Department of Clinical Medicine, University Hospital Mannheim, University of Heidelberg, Germany

Abstract

ABSTRACT

Direct thrombin inhibitors (DTIs) such as hirudins and melagatran are currently developed for antithrombotic therapy. They should possess some advantages over the currently used low-molecular-weight heparins (LMWHs). They may also act through an inhibition of thrombin-induced platelet activation. The antithrombotic effects of DTIs and of LMWHs were investigated in an ex vivo thrombosis model with human blood in order to analyze the inhibition of thrombin-antithrombin as well as the platelet factor 4 formation. The data show that DTIs inhibit both fibrin formation and platelet activation, which is of clinical relevance especially for melagatran.

KEYWORDS

Direct thrombin inhibitor - melagatran - low-molecular-weight heparin - platelet factor 4 - thrombin formation

Full Text

References

REFERENCES

1 Zokai K, Piazolo L, Harenberg J. Effect of thrombin inhibitors and a glycoprotein IIb/IIIa receptor antagonist in an ex vivo human experimental thrombosis model. Semin Thromb Hemost . 2001; 27 531-536
2 Harenberg J, Schuler M, Waibel S T, Heptner W, Zimmermann R. Influence of low molecular weight heparin on fibrin formation and platelet aggregation. Haemostasis . 1985; 15 29-30
3 Harenberg J. Thrombin-antithrombin (TAT) complexes. In: Jespersen J, Bertina RM, Haverkate F, eds. ECAT Assay Procedures Laboratory Techniques in Thrombosis A Manual. 2nd rev ed. Dordrecht: Kluwer Academic Publishers 1998: 209-216
4 Hara T, Yokoyama A, Morishima Y, Kunitada S. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Thromb Res . 1995; 80 99-104
5 Tapparelli C, Metternich R, Gfeller P, Gafner B, Powling M. Antithrombotic activity in vivo of SDZ 217-766, a low-molecular weight thrombin inhibitor in comparison to heparin. Thromb Haemost . 1995; 73 641-647
6 Dickneite G, Seiffge D, Diehl K H. Pharmacological characterization of a new 4-amidinophenylalanine thrombin-inhibitor (CRC 220). Thromb Res . 1995; 77 357-368
7 Greinacher A, Völpel H, Janssens U, for the HIT Investigators Group et al. Recombinant hirudin (Lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia. A prospective study. Circulation . 1999; 99 73-80
8 Harenberg J, Huhle G, Piazolo L, Wang L U, Heene D L. Anticoagulation in patients with heparin-induced thrombocytopenia type II. Semin Thromb Hemost . 1997; 23 189-196
9 Lewis B E, Wallis D E, Berkowitz S D. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation . 2001; 103 1838-1843
10 Eriksson U G, Frison L, Gustafsson D. Effect of melagatran, the active form of the oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376/95), on activated partial thromboplastin time in orthopaedic surgery patients treated to prevent deep vein thrombosis and pulmonary embolism (Abst). Thromb Haemost . 2001; Suppl P3093
11 Eriksson B I, Ögren M, Agnelli G. The oral direct thrombin inhibitor ximelagatran (pINN, formerly H 376/95) and its subcutaneous form melagatran compared with enoxaparin as thromboprophylaxis after total hip or total knee replacement (Abst). Thromb Haemost . 2001; Suppl OC1638
12 Eriksson H, Wahlander K, Gustafsson D, Welin L, Schulman S. Efficacy and tolerability of the novel, oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376/95), compared with standard therapy for the treatment of acute deep vein thrombosis (Abst). Thromb Haemost . 2001; Suppl OC2348
13 Francis C W, Davidson B L, Berkowitz S D. Randomised, double-blind, comparative study of ximelagatran (pINN, formerly H 376/95), an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee arthroplasty (TKA) (Abst). Thromb Haemost . 2001; Suppl OC44
14 Gray E, Tubbs J, Thomas S. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity. Thromb Haemost . 1995; 73 675-679
15 Orvim U, Barstad R M, Vlasuk G P, Sakariassen K S. Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis. Arterioscler Thromb Vasc Biol . 1995; 15 2188-2194
16 Hirigoyen M B, Zhang W X, Weinberg H. A standardized model of microvenous thrombosis. J Reconstr Microsurg . 1995; 11 455-459
17 Delon-Martin C, Vogt C, Chignier E. Venous thrombosis generation by means of high-intensity focused ultrasound. Ultrasound Med Biol . 1995; 21 113-119
18 Krupinski K, Ferber H, Breddin H K, Bielawiec M. The antithrombotic effect of thromboxane receptor antagonist HN 11500 on thrombus formation in laser thrombosis model and platelet function tests. Acta Haematol Pol . 1994; 25 235-242
19 Jourdan A, Aguejouf O, Imbault P, Doutremepuich F, Inamo J. Experimental thrombosis model induced by free radicals. Application to aspirin and other different substances. Thromb Res . 1995; 79 109-123
20 Saniabadi A R, Umemura K, Matsumoto N, Sakuma S, Nakashima M. Vessel wall injury and arterial thrombosis induced by a photochemical reaction. Thromb Haemost . 1995; 73 868-872